Compound sixty has an extremely high affinity to MDM2 (Ki < one nM), strong cellular action, and an excellent oral pharmacokinetic profile. Compound sixty is capable of obtaining complete and very long-lasting tumor regression in vivo and is also currently in stage I medical trials for most cancers treatment. In https://lorenzomtyhj.blogsumer.com/31346407/dsg-crosslinker-no-further-a-mystery